Publications by authors named "Mayu Takeyama"
What Is Known And Objective: Since its introduction in April 2012, denosumab has been administered to approximately 7,300 patients as of August 2012, and 32 cases of serious hypocalcaemia after denosumab administration, including two deaths, have been reported in Japan. A Dear Healthcare Professional Letter of Rapid Safety Communication ('Blue letter') was released to warn about the risks of hypocalcaemia associated with denosumab. The goal of this study therefore was to measure the impact of regulatory action on denosumab-induced hypocalcaemia in Japan by using an electronic medical information database (MID).
View Article and Find Full Text PDFWhat Is Known And Objective: This study used electronic medical records to identify risk factors and establish a detection algorithm for denosumab-induced hypocalcaemia.
Methods: We identified 201 patients with cancer who were initially prescribed denosumab. Hypocalcaemia was defined as an adjusted serum calcium level of ≤2.
Article Synopsis
- The study investigates the effectiveness of a regulatory action taken in Japan in 2012 concerning the antibody Denosumab (DEN), aimed at reducing severe hypocalcemia risks.
- An analysis of data from the Japanese Adverse Drug Event Report database (JADER) found a significant decrease in reported hypocalcemia cases associated with DEN after the regulatory action.
- The findings indicate that the regulatory interventions were effective in reducing hypocalcemia signals linked to DEN, but further research is required to validate these results.
Oral carcinoma patients with inactivation of mucosa-associated lymphoid tissue 1 (MALT1) expression worsen their prognoses. Although the genetic mutation could be responsible for the inactivation, no information is available at present. In the present study, genomic DNA of oral carcinoma cells (HOC313, TSU, HSC2, HSC3, KOSC2, KOSC3, SCCKN, OSC19, Ca9.
View Article and Find Full Text PDF